ClinicalTrials.gg
WithdrawnNCT00838253Updated Oct 23, 2014

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

A Phase 2 interventional study of Istaroxime and Istaroxime in Heart Failure, sponsored by Debiopharm International SA. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-23.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was not started due to a re-evaluation of the istaroxime development program

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of istaroxime in patients hospitalized for Acute Decompensated Heart Failure (ADHF) not requiring inotropic therapy.This will be done by comparing the hemodynamic effect of a 24-hour infusion of three different doses of the drug versus placebo. Efficacy will be measured as a change in Pulmonary Capillary Wedge Pressure from pre-infusion to 6 hours after infusion start. Secondary objectives will include the evaluation of clinical efficacy and safety through assessment of cardiovascular and renal tolerability as well as changes in biological markers such as brain natriuretic peptide (BNP) and troponin I (TNI), and the neurohormones renin and aldosterone and also to assess the pharmacokinetics of istaroxime and its metabolites.

Read the detailed description

The 32-day study includes a 48-hour screening period, a 30-minute to 2-hour pre treatment period, a maximum 2-hour period for randomization and measurement of baseline values, a 24-hour treatment period, and a 96-hour post-treatment period. A 25-day follow-up period including a visit on Day 30 will take place after the active phase of the study When considered to be eligible, a first cohort of 88 patients will be randomized in a 3:1 ratio to receive 24-hrs treatment with istaroxime 0.5 μg/kg/min or placebo. If after the continuous safety monitoring and interim analyses the DMC determines that there are no safety issues with this dose, a second cohort of 88 patients will be randomized in a 3:1 ratio to receive 24-hrs treatment with istaroxime 1.0 μg/kg/min or placebo. If after the continuous safety monitoring and interim analyses of the second cohort the DMC determines that there are no safety issues with this dose, a third cohort of 88 patients will be randomized in a 3:1 ratio to receive 24-hrs treatment with istaroxime 1.5 μg/kg/min or placebo. In all cohorts, patients will receive standard of care therapy.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Acute Heart Failure
  • Inotropes
  • Lusitropic agents
  • Istaroxime
  • Debio 0614
03

In context

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Lead sponsor

Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years;
  • Admission for ADHF
  • Systolic blood pressure ≤ 120 mmHg;
  • (EF) ≤ 35 %
  • Signed .

Randomization inclusion criteria:

  • Persistence of ADHF signs despite initial treatment with i.v. diuretics and/or vasodilators;
  • Cardiac index ≤ 2.5 L/min/m²;
  • Pulmonary capillary wedge pressure ≥ 20 mmHg
  • Systolic BP between 85 and 120 mmHg (limits included) without signs or symptoms of hypoperfusion

Exclusion criteria

Exclusion Criteria:

  • Main screening exclusion criteria:
  • Positive pregnancy test in females of ;
  • Systolic blood pressure \< 85 mmHg or > 120 mmHg;
  • Oral treatment with digoxin within one week before current hospitalization;
  • Any inotrope administered during the current hospitalization
  • Presence of cardiogenic shock or its occurrence within the past month;
  • Acute coronary syndrome within the past 3 months;
  • Coronary artery bypass graft or percutaneous coronary intervention within the past month;
  • Stroke within the past 6 months;
  • Atrial fibrillation with uncontrolled HR (HR > 100 beats per minute (bpm);
  • Life threatening ventricular arrhythmia or ICD (implantable cardioverter defibrillator) shock within the past month;
  • Presence of a CRT (cardiac resynchronization therapy), ICD or pacemaker devices implanted within the past month;
  • Second or third degree atrio-ventricular block without pacemaker;
  • Abnormal safety lab values obtained within the last 24 hours of the screening period prior to pulmonary arterial catheter (PAC) insertion

Randomization exclusion criteria:

  • Any inotrope administered during the current hospitalization period
  • Heart rate > 120 bpm or \< 50 bpm;
  • cTnI > 0.5 ng/mL or cTnI > and > 1.25x the first screening assessment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    Drug: Istaroxime

  • Experimental
    2

    Drug: Istaroxime

  • Experimental
    3

    Drug: Istaroxime

  • Placebo comparator
    4

    Drug: Placebo

Interventions

  • Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours

  • Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours

  • Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours

  • DrugPlacebo

    Placebo continuous i.v. infusion for 24 hours

06

What researchers measure

Primary outcomes

  1. PCWP change from baseline

    Time frame: 6 hours after infusion start

Secondary outcomes

  1. PCWP, MRAP, SVR, PVR, Cardiac Index and SBP

    Time frame: 1, 3, 6, 12 and 24 hours after infusion start and 1 and 3 hours after infusion end.

  2. Safety parameters and drug pharmacokinetics

    Time frame: 1, 3, 6, 12 and 24 hours after infusion start and 1 and 3 hours after infusion end

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008 Jun 10;51(23):2276-85. doi: 10.1016/j.jacc.2008.03.015. Epub 2008 Apr 9. PubMed 18534276 ↗

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00838253
First posted
Feb 6, 2009
Start date
Jun 2009
Last update
Oct 23, 2014

Study contacts

Hein Van Ingen, M.D.
study director · Debiopharm International SA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istaroxime

Start the discussion